MGTX

Company Overview — What Does MeiraGTx Holdings plc Do?

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York. MeiraGTx Holdings plc (MGTX) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Alexandria Forbes and employs approximately 300 people. With a market capitalization of $740M, MGTX is one of the notable companies in the Healthcare sector.

MeiraGTx Holdings plc (MGTX) Stock Rating — Hold (April 2026)

As of April 2026, MeiraGTx Holdings plc receives a Hold rating with a composite score of 30.4/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.MGTX ranks #1,887 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, MeiraGTx Holdings plc ranks #198 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

MGTX Stock Price and 52-Week Range

MeiraGTx Holdings plc (MGTX) currently trades at $9.07. The stock lost $0.27 (2.9%) in the most recent trading session. The 52-week high for MGTX is $9.73, which means the stock is currently trading -6.8% from its annual peak. The 52-week low is $4.55, putting the stock 99.3% above its annual trough. Recent trading volume was 518K shares, suggesting relatively thin trading activity.

Is MGTX Overvalued or Undervalued? — Valuation Analysis

MeiraGTx Holdings plc (MGTX) carries a value factor score of 22/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 45.73x, compared to 1.66x for the average Healthcare stock.

At current multiples, MeiraGTx Holdings plc trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

MeiraGTx Holdings plc Profitability — ROE, Margins, and Quality Score

MeiraGTx Holdings plc (MGTX) earns a quality factor score of 13/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -7879.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -69.0% versus the sector average of -33.1%.

On a margin basis, MeiraGTx Holdings plc reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -3743.1% (sector: -66.1%). Net profit margin stands at -3951.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 45.4% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

MGTX Debt, Balance Sheet, and Financial Health

MeiraGTx Holdings plc has a debt-to-equity ratio of -183.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 0.75x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $74M. Cash and equivalents stand at $15M.

MGTX has a beta of 1.22, meaning it is more volatile than the broader market — a $10,000 investment in MGTX would be expected to move 21.5% more than the S&P 500 on any given day. The stability factor score for MeiraGTx Holdings plc is 39/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

MeiraGTx Holdings plc Revenue and Earnings History — Quarterly Trend

In TTM 2026, MeiraGTx Holdings plc reported revenue of $17M and earnings per share (EPS) of $-1.42. Net income for the quarter was $-169M. Gross margin was 100.0%. Operating income came in at $-172M.

In FY 2025, MeiraGTx Holdings plc reported revenue of $81M and earnings per share (EPS) of $-1.42. Net income for the quarter was $-114M. Revenue grew 144.6% year-over-year compared to FY 2024. Operating income came in at $-106M.

In Q3 2025, MeiraGTx Holdings plc reported revenue of $410,000 and earnings per share (EPS) of $-0.62. Net income for the quarter was $-51M. Revenue grew -96.2% year-over-year compared to Q3 2024. Operating income came in at $-46M.

In Q2 2025, MeiraGTx Holdings plc reported revenue of $4M and earnings per share (EPS) of $-0.48. Net income for the quarter was $-39M. Revenue grew 1208.9% year-over-year compared to Q2 2024. Operating income came in at $-45M.

Over the past 8 quarters, MeiraGTx Holdings plc has demonstrated a growth trajectory, with revenue expanding from $282,000 to $17M. Investors analyzing MGTX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

MGTX Dividend Yield and Income Analysis

MeiraGTx Holdings plc (MGTX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

MGTX Momentum and Technical Analysis Profile

MeiraGTx Holdings plc (MGTX) has a momentum factor score of 48/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 23/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 53/100 reflects moderate short selling activity.

MGTX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, MeiraGTx Holdings plc (MGTX) ranks #198 out of 838 stocks based on the Blank Capital composite score. This places MGTX in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing MGTX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MGTX vs S&P 500 (SPY) comparison to assess how MeiraGTx Holdings plc stacks up against the broader market across all factor dimensions.

MGTX Next Earnings Date

No upcoming earnings date has been announced for MeiraGTx Holdings plc (MGTX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy MGTX? — Investment Thesis Summary

MeiraGTx Holdings plc presents a balanced picture with arguments on both sides. The quality score of 13/100 flags below-average profitability. The value score of 22/100 indicates premium valuation. High volatility (stability score 39/100) increases portfolio risk.

In summary, MeiraGTx Holdings plc (MGTX) earns a Hold rating with a composite score of 30.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MGTX stock.

Related Resources for MGTX Investors

Explore more research and tools: MGTX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MGTX head-to-head with peers: MGTX vs AZN, MGTX vs SLGL, MGTX vs VMD.